<rst>
<header>
	<relations>
			<rel name="means" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3. Results and Discussion</segment>
<segment id="2" parent="1002" relname="span">During the drug design process ,</segment>
<segment id="3" parent="1004" relname="span">to assess the potential druggability of a compound as a new starting point , some initial rules like drug-likeness</segment>
<segment id="4" parent="3" relname="elaboration">( as defined by Lipinski and colleagues in 1997 ) ,</segment>
<segment id="5" parent="1006" relname="span">lead-likeness</segment>
<segment id="6" parent="5" relname="elaboration">( as defined by Oprea )</segment>
<segment id="7" parent="1005" relname="joint">and known drug space , are usually applied .</segment>
<segment id="8" parent="1008" relname="span">In general , the rules</segment>
<segment id="9" parent="8" relname="purpose">to characterise/filter compound collections are based upon physicochemical parameters , e. g. , logP , logS , MW , TPSA , MR , RotN , HBA and HBD , among others .</segment>
<segment id="10" parent="1009" relname="span">As a result , it would be interesting to assess how proteasome inhibitors are positioned with respect to the typically expected “ drug-like ” chemical space .</segment>
<segment id="11" parent="1011" relname="span">To do so , we performed a comprehensive analysis of the 680 small-molecules proteasome inhibitors dataset</segment>
<segment id="12" parent="1012" relname="span">spanning a large range of activity</segment>
<segment id="13" parent="12" relname="elaboration">( 0.08 nM &lt; IC50 ≤ 150,000 nM ) .</segment>
<segment id="14" parent="1014" relname="span">This entailed looking at chemical space distribution , scaffold similarity and the extraction of chemical rules with machine learning ,</segment>
<segment id="15" parent="1016" relname="span">using either direct structural information</segment>
<segment id="16" parent="15" relname="elaboration">( scaffolds and Morgan fingerprints )</segment>
<segment id="17" parent="1018" relname="span">or being based on 21 general molecular</segment>
<segment id="18" parent="17" relname="elaboration">( QuaSAR )</segment>
<segment id="19" parent="1017" relname="same_unit">descriptors .</segment>
<segment id="20" parent="1020" relname="span">This set of analyses was ultimately employed</segment>
<segment id="21" parent="1021" relname="span">to produce meaningful chemical patterns</segment>
<segment id="22" parent="21" relname="elaboration">that are correlated with proteasome inhibitory activity .</segment>
<segment id="23" parent="1023" relname="span">The dataset comprises only human proteasome activity data for the CT-L catalytic site ,</segment>
<segment id="24" parent="1024" relname="joint">as this is the only site with the largest number of compounds ,</segment>
<segment id="25" parent="1024" relname="joint">and is divided into four classes .</segment>
<segment id="26" parent="1026" relname="span">Full data are available in Table S1 .</segment>
<segment id="27" parent="1027" relname="span">Analysis of chemical space distribution and the scaffold similarity of proteasome inhibitors .</segment>
<segment id="28" parent="1028" relname="span">First , we analyzed human proteasome inhibitors ’ chemical space distribution .</segment>
<segment id="29" parent="1029" relname="span">To address this analysis ,</segment>
<segment id="30" parent="1030" relname="span">chemical space was defined by the t-SNE calculation</segment>
<segment id="31" parent="1031" relname="span">applied to the 21 calculated molecular descriptors</segment>
<segment id="32" parent="1032" relname="span">listed in the Supplementary Information</segment>
<segment id="33" parent="32" relname="elaboration">( Table S1 ) .</segment>
<segment id="34" parent="1034" relname="joint">The proximity in a t-SNE plot is relative in nature ,</segment>
<segment id="35" parent="1035" relname="span">and the distance between points simply represents relative proximity</segment>
<segment id="36" parent="35" relname="elaboration">( i. e. , it is not a direct scaling from real distances in the 21 dimensional space ) .</segment>
<segment id="37" parent="1038" relname="preparation">In</segment>
<segment id="38" parent="1039" relname="span">Figure 4</segment>
<segment id="39" parent="38" relname="restatement">( left )</segment>
<segment id="40" parent="1041" relname="preparation">the difference of distribution of the four activity classes is easily perceptible ,</segment>
<segment id="41" parent="1042" relname="span">with the most active compounds</segment>
<segment id="42" parent="41" relname="elaboration">( class A , purple )</segment>
<segment id="43" parent="1044" relname="span">having close to half of its compounds</segment>
<segment id="44" parent="43" relname="restatement">( ~47 % )</segment>
<segment id="45" parent="1045" relname="span">in the top-right quadrant of the plot ,</segment>
<segment id="46" parent="1049" relname="span">while the least active compounds</segment>
<segment id="47" parent="46" relname="elaboration">( class D , orange )</segment>
<segment id="48" parent="1048" relname="same_unit">are mainly concentrated in the bottom-left quadrant</segment>
<segment id="49" parent="1048" relname="elaboration">( ~58 % of class D compounds ) ,</segment>
<segment id="50" parent="1046" relname="span">as quantified in</segment>
<segment id="51" parent="1051" relname="span">Figure 4</segment>
<segment id="52" parent="51" relname="restatement">( right ) .</segment>
<segment id="53" parent="1054" relname="span">Classes B</segment>
<segment id="54" parent="53" relname="elaboration">( blue )</segment>
<segment id="55" parent="1057" relname="span">and C</segment>
<segment id="56" parent="55" relname="restatement">( green )</segment>
<segment id="57" parent="1056" relname="same_unit">have a more disperse distribution ,</segment>
<segment id="58" parent="1055" relname="span">but show some higher density areas close to the bottom-left corner .</segment>
<segment id="59" parent="1061" relname="attribution">This indicates</segment>
<segment id="60" parent="1061" relname="joint">that class D , for example , is fundamentally different to the remaining classes from a structural and physicochemical level ,</segment>
<segment id="61" parent="1062" relname="span">and therefore supports the existence of a SAR in the proteasome inhibitors</segment>
<segment id="62" parent="61" relname="elaboration">developed in the last 20 years .</segment>
<segment id="63" parent="1063" relname="span">Additionally , no particular cluster was formed with a single class ,</segment>
<segment id="64" parent="1065" relname="span">which means there is no particular location in chemical space</segment>
<segment id="65" parent="1066" relname="span">( at least one</segment>
<segment id="66" parent="1067" relname="span">that is defined by the descriptors</segment>
<segment id="67" parent="66" relname="elaboration">that we considered )</segment>
<segment id="68" parent="1065" relname="elaboration">which is reserved to one single class .</segment>
<segment id="69" parent="1070" relname="attribution">This observation indicates</segment>
<segment id="70" parent="1070" relname="span">that carrying out compound selection biased for physicochemical similarity to known inhibitors might be a good initial filter</segment>
<segment id="71" parent="70" relname="purpose">to enrich the set of compound candidates with active hits .</segment>
<segment id="72" parent="1072" relname="span">Next , we wanted to investigate what characteristics are responsible for the differences between classes in the chemical space distribution .</segment>
<segment id="73" parent="1073" relname="span">Upon applying the Tc</segment>
<segment id="74" parent="1074" relname="span">to characterize the similarity between Murcko scaffolds within each class ,</segment>
<segment id="75" parent="1075" relname="span">we observed a high diversity in the dataset , not just within each class , but also between the different classes ,</segment>
<segment id="76" parent="1076" relname="span">with most pairs of compounds showing a Tc below 0.5</segment>
<segment id="77" parent="1077" relname="span">that represents a considerable dissimilarity</segment>
<segment id="78" parent="77" relname="elaboration">(</segment>
<segment id="79" parent="1079" relname="preparation">Figure 5</segment>
<segment id="80" parent="1079" relname="joint">) .</segment>
<segment id="81" parent="1080" relname="sequence">Nonetheless a clear trend of correlation between activity and similarity is observed .</segment>
<segment id="82" parent="1083" relname="concession">The scaffolds of class B differ negligibly from class A ,</segment>
<segment id="83" parent="1083" relname="span">however , class C shows a two-peak distribution</segment>
<segment id="84" parent="1085" relname="attribution">which suggests</segment>
<segment id="85" parent="1085" relname="span">it contains scaffolds similar to both classes A/B , as well as with lower activity compounds</segment>
<segment id="86" parent="85" relname="elaboration">( class D ) .</segment>
<segment id="87" parent="1087" relname="span">This is probably a result of the practical strategies</segment>
<segment id="88" parent="1088" relname="span">applied in medicinal chemistry</segment>
<segment id="89" parent="1089" relname="span">where inactive structures are modified/derivatized</segment>
<segment id="90" parent="1090" relname="span">to meet or better resemble substructures</segment>
<segment id="91" parent="90" relname="elaboration">seen among actives ,</segment>
<segment id="92" parent="1092" relname="same_unit">thus creating this transition from A to D.</segment>
<segment id="93" parent="1094" relname="circumstance">As concluded from the chemical space observation ,</segment>
<segment id="94" parent="1095" relname="attribution">this also shows</segment>
<segment id="95" parent="1097" relname="span">that functionalizing scaffolds from more potent compounds</segment>
<segment id="96" parent="95" relname="elaboration">( class A/B )</segment>
<segment id="97" parent="1096" relname="same_unit">might be a feasible initial strategy</segment>
<segment id="98" parent="1096" relname="purpose">to find new actives .</segment>
<segment id="99" parent="1098" relname="span">However , selected scaffolds should also be sufficiently dissimilar to the lower activity scaffolds ,</segment>
<segment id="100" parent="1099" relname="span">effectively avoiding the right-end tail of the class D</segment>
<segment id="101" parent="1100" relname="span">( i. e. , the most similar scaffolds to A ,</segment>
<segment id="102" parent="101" relname="elaboration">which are still largely inactive ) .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1007" relname="background"/>
<group id="1003" type="multinuc" parent="2" relname="purpose"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1003" relname="same_unit"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="multinuc" parent="1001" relname="span"/>
<group id="1008" type="span" parent="1007" relname="joint"/>
<group id="1009" type="span" parent="1007" relname="joint"/>
<group id="1010" type="multinuc" parent="10" relname="purpose"/>
<group id="1011" type="span" parent="1010" relname="sequence"/>
<group id="1012" type="span" parent="11" relname="elaboration"/>
<group id="1013" type="multinuc" parent="1010" relname="sequence"/>
<group id="1014" type="span" parent="1013" relname="sequence"/>
<group id="1015" type="multinuc" parent="14" relname="means"/>
<group id="1016" type="span" parent="1015" relname="contrast"/>
<group id="1017" type="multinuc" parent="1015" relname="contrast"/>
<group id="1018" type="span" parent="1017" relname="same_unit"/>
<group id="1019" type="span" parent="1013" relname="sequence"/>
<group id="1020" type="span" parent="1022" relname="preparation"/>
<group id="1021" type="span" parent="20" relname="purpose"/>
<group id="1022" type="multinuc" parent="1019" relname="span"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="multinuc" parent="23" relname="elaboration"/>
<group id="1025" type="multinuc" parent="1022" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1028" type="span" parent="27" relname="elaboration"/>
<group id="1029" type="span" parent="28" relname="purpose"/>
<group id="1030" type="span" parent="29" relname="elaboration"/>
<group id="1031" type="span" parent="30" relname="elaboration"/>
<group id="1032" type="span" parent="31" relname="elaboration"/>
<group id="1033" type="multinuc" parent="1025" relname="joint"/>
<group id="1034" type="multinuc" parent="1033" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1033" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="span"/>
<group id="1039" type="span" parent="1040" relname="preparation"/>
<group id="1040" type="span" parent="1038" relname="span"/>
<group id="1041" type="multinuc" parent="1040" relname="span"/>
<group id="1042" type="span" parent="1041" relname="same_unit"/>
<group id="1043" type="multinuc" parent="1041" relname="same_unit"/>
<group id="1044" type="span" parent="1043" relname="same_unit"/>
<group id="1045" type="span" parent="1043" relname="same_unit"/>
<group id="1046" type="span" parent="45" relname="circumstance"/>
<group id="1047" type="span" parent="50" relname="concession"/>
<group id="1048" type="multinuc" parent="1047" relname="span"/>
<group id="1049" type="span" parent="1048" relname="same_unit"/>
<group id="1050" type="span" parent="1036" relname="joint"/>
<group id="1051" type="span" parent="1052" relname="preparation"/>
<group id="1052" type="multinuc" parent="1050" relname="span"/>
<group id="1053" type="multinuc" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1053" relname="joint"/>
<group id="1055" type="span" parent="1053" relname="joint"/>
<group id="1056" type="multinuc" parent="58" relname="concession"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="multinuc" parent="1052" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="sequence"/>
<group id="1060" type="span" parent="1059" relname="span"/>
<group id="1061" type="multinuc" parent="1060" relname="span"/>
<group id="1062" type="span" parent="1061" relname="joint"/>
<group id="1063" type="span" parent="1060" relname="elaboration"/>
<group id="1064" type="span" parent="63" relname="elaboration"/>
<group id="1065" type="span" parent="1064" relname="span"/>
<group id="1066" type="span" parent="64" relname="elaboration"/>
<group id="1067" type="span" parent="65" relname="elaboration"/>
<group id="1068" type="multinuc" parent="1058" relname="sequence"/>
<group id="1069" type="span" parent="1068" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="span"/>
<group id="1071" type="multinuc" parent="1068" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="72" relname="evidence"/>
<group id="1074" type="span" parent="73" relname="purpose"/>
<group id="1075" type="span" parent="74" relname="evidence"/>
<group id="1076" type="span" parent="75" relname="evidence"/>
<group id="1077" type="span" parent="76" relname="elaboration"/>
<group id="1078" type="span" parent="1071" relname="joint"/>
<group id="1079" type="multinuc" parent="1078" relname="span"/>
<group id="1080" type="multinuc" parent="1079" relname="joint"/>
<group id="1081" type="multinuc" parent="1080" relname="sequence"/>
<group id="1082" type="span" parent="1081" relname="joint"/>
<group id="1083" type="span" parent="1082" relname="span"/>
<group id="1084" type="span" parent="83" relname="elaboration"/>
<group id="1085" type="span" parent="1084" relname="span"/>
<group id="1086" type="multinuc" parent="1081" relname="joint"/>
<group id="1087" type="span" parent="1086" relname="joint"/>
<group id="1088" type="span" parent="87" relname="elaboration"/>
<group id="1089" type="span" parent="88" relname="elaboration"/>
<group id="1090" type="span" parent="89" relname="purpose"/>
<group id="1091" type="multinuc" parent="1086" relname="joint"/>
<group id="1092" type="multinuc" parent="1091" relname="contrast"/>
<group id="1093" type="span" parent="1092" relname="same_unit"/>
<group id="1094" type="span" parent="1093" relname="span"/>
<group id="1095" type="span" parent="1094" relname="span"/>
<group id="1096" type="multinuc" parent="1095" relname="span"/>
<group id="1097" type="span" parent="1096" relname="same_unit"/>
<group id="1098" type="span" parent="1091" relname="contrast"/>
<group id="1099" type="span" parent="99" relname="elaboration"/>
<group id="1100" type="span" parent="100" relname="elaboration"/>
	</body>
</rst>
